Antipsychotic	B:C0040615
Drugs	I:C0040615
and	O
Risk	O
of	O
Hip	O
Fracture	I:C0019557
in	O
People	O
Aged	O
60	O
and	O
Older	O
in	O
Norway	O
.	O

Antipsychotic	O
Drugs	I:C0040615
and	O
Risk	O
of	O
Hip	B:C0019557
Fracture	I:C0019557
in	O
People	O
Aged	O
60	O
and	O
Older	O
in	O
Norway	O
.	O

Antipsychotic	O
Drugs	I:C0040615
and	O
Risk	O
of	O
Hip	O
Fracture	I:C0019557
in	O
People	B:C0027361
Aged	O
60	O
and	O
Older	O
in	O
Norway	O
.	O

Antipsychotic	O
Drugs	I:C0040615
and	O
Risk	O
of	O
Hip	O
Fracture	I:C0019557
in	O
People	O
Aged	O
60	O
and	O
Older	B:C0001792
in	O
Norway	O
.	O

Antipsychotic	O
Drugs	I:C0040615
and	O
Risk	O
of	O
Hip	O
Fracture	I:C0019557
in	O
People	O
Aged	O
60	O
and	O
Older	O
in	O
Norway	B:C0028423
.	O

To	O
examine	O
associations	O
between	O
exposure	O
to	O
various	O
subgroups	O
of	O
antipsychotic	B:C0040615
drugs	I:C0040615
and	O
risk	O
of	O
hip	O
fracture	I:C0019557
in	O
older	O
adults	O
.	O

To	O
examine	O
associations	O
between	O
exposure	O
to	O
various	O
subgroups	O
of	O
antipsychotic	O
drugs	I:C0040615
and	O
risk	O
of	O
hip	B:C0019557
fracture	I:C0019557
in	O
older	O
adults	O
.	O

To	O
examine	O
associations	O
between	O
exposure	O
to	O
various	O
subgroups	O
of	O
antipsychotic	O
drugs	I:C0040615
and	O
risk	O
of	O
hip	O
fracture	I:C0019557
in	O
older	B:C0001792
adults	O
.	O

Norway	B:C0028423
,	O
2005	O
-	O
2010	O
.	O

Everyone	O
living	O
in	O
Norway	B:C0028423
born	O
before	O
1945	O
(	O
N	O
=	O
906,422	O
)	O
.	O

Information	O
was	O
obtained	O
on	O
all	O
prescriptions	B:C0033081
of	O
antipsychotic	O
drugs	I:C0040615
dispensed	O
from	O
2004	O
to	O
2010	O
(	O
Norwegian	O
Prescription	I:C0242356
Database	I:C0242356
)	O
and	O
data	O
on	O
all	O
primary	O
hip	O
fractures	I:C0019557
from	O
2005	O
to	O
2010	O
(	O
Norwegian	O
Hip	I:C0282574
Fracture	I:C0282574
Registry	I:C0282574
)	O
.	O

Information	O
was	O
obtained	O
on	O
all	O
prescriptions	O
of	O
antipsychotic	B:C0040615
drugs	I:C0040615
dispensed	O
from	O
2004	O
to	O
2010	O
(	O
Norwegian	O
Prescription	I:C0242356
Database	I:C0242356
)	O
and	O
data	O
on	O
all	O
primary	O
hip	O
fractures	I:C0019557
from	O
2005	O
to	O
2010	O
(	O
Norwegian	O
Hip	I:C0282574
Fracture	I:C0282574
Registry	I:C0282574
)	O
.	O

Information	O
was	O
obtained	O
on	O
all	O
prescriptions	O
of	O
antipsychotic	O
drugs	I:C0040615
dispensed	O
from	O
2004	O
to	O
2010	O
(	O
Norwegian	B:C0242356
Prescription	I:C0242356
Database	I:C0242356
)	O
and	O
data	O
on	O
all	O
primary	O
hip	O
fractures	I:C0019557
from	O
2005	O
to	O
2010	O
(	O
Norwegian	O
Hip	I:C0282574
Fracture	I:C0282574
Registry	I:C0282574
)	O
.	O

Information	O
was	O
obtained	O
on	O
all	O
prescriptions	O
of	O
antipsychotic	O
drugs	I:C0040615
dispensed	O
from	O
2004	O
to	O
2010	O
(	O
Norwegian	O
Prescription	I:C0242356
Database	I:C0242356
)	O
and	O
data	O
on	O
all	O
primary	O
hip	B:C0019557
fractures	I:C0019557
from	O
2005	O
to	O
2010	O
(	O
Norwegian	O
Hip	I:C0282574
Fracture	I:C0282574
Registry	I:C0282574
)	O
.	O

Information	O
was	O
obtained	O
on	O
all	O
prescriptions	O
of	O
antipsychotic	O
drugs	I:C0040615
dispensed	O
from	O
2004	O
to	O
2010	O
(	O
Norwegian	O
Prescription	I:C0242356
Database	I:C0242356
)	O
and	O
data	O
on	O
all	O
primary	O
hip	O
fractures	I:C0019557
from	O
2005	O
to	O
2010	O
(	O
Norwegian	B:C0282574
Hip	I:C0282574
Fracture	I:C0282574
Registry	I:C0282574
)	O
.	O

Incidence	O
rates	O
of	O
hip	B:C0019557
fracture	I:C0019557
during	O
person	O
-	O
time	O
exposed	O
and	O
unexposed	O
to	O
antipsychotic	O
drugs	I:C0040615
were	O
compared	O
by	O
calculating	O
the	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
.	O

Incidence	O
rates	O
of	O
hip	O
fracture	I:C0019557
during	O
person	O
-	O
time	O
exposed	O
and	O
unexposed	O
to	O
antipsychotic	B:C0040615
drugs	I:C0040615
were	O
compared	O
by	O
calculating	O
the	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
.	O

Thirty	O
-	O
nine	O
thousand	O
nine	O
hundred	O
thirty	O
-	O
eight	O
(	O
4.4	O
%	O
)	O
participants	B:C0679646
experienced	O
a	O
primary	O
hip	O
fracture	I:C0019557
.	O

Thirty	O
-	O
nine	O
thousand	O
nine	O
hundred	O
thirty	O
-	O
eight	O
(	O
4.4	O
%	O
)	O
participants	O
experienced	O
a	O
primary	O
hip	B:C0019557
fracture	I:C0019557
.	O

Greater	O
risk	O
of	O
hip	B:C0019557
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	B:C0040615
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	B:C0008902
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	B:C0040615
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	B:C0008902
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	B:C0040615
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	B:C0033371
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	B:C0040615
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	B:C0033371
-	O
elevating	O
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

Greater	O
risk	O
of	O
hip	O
fracture	I:C0019557
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	O
(	O
SIR	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.9	O
-	O
2.1	O
)	O
,	O
first	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
2.2	O
)	O
,	O
second	O
-	I:C0008902
generation	I:C0008902
antipsychotics	O
(	O
SIR	O
=	O
2.2	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.4	O
)	O
,	O
prolactin	O
-	O
sparing	O
antipsychotics	O
(	O
SIR	O
=	O
2.4	O
,	O
95	O
%	O
CI	O
=	O
1.8	O
-	O
3.1	O
)	O
and	O
prolactin	O
-	O
elevating	O
antipsychotics	B:C0040615
(	O
SIR	O
=	O
2.0	O
,	O
95	O
%	O
CI	O
=	O
1.9	O
-	O
2.2	O
)	O
.	O

In	O
people	B:C0027361
aged	O
60	O
and	O
older	O
in	O
Norway	O
,	O
those	O
who	O
took	O
an	O
antipsychotic	O
drug	I:C0040615
had	O
twice	O
the	O
risk	O
of	O
sustaining	O
a	O
hip	O
fracture	I:C0019557
during	O
exposure	O
than	O
during	O
nonexposure	O
.	O

In	O
people	O
aged	O
60	O
and	O
older	B:C0001792
in	O
Norway	O
,	O
those	O
who	O
took	O
an	O
antipsychotic	O
drug	I:C0040615
had	O
twice	O
the	O
risk	O
of	O
sustaining	O
a	O
hip	O
fracture	I:C0019557
during	O
exposure	O
than	O
during	O
nonexposure	O
.	O

In	O
people	O
aged	O
60	O
and	O
older	O
in	O
Norway	B:C0028423
,	O
those	O
who	O
took	O
an	O
antipsychotic	O
drug	I:C0040615
had	O
twice	O
the	O
risk	O
of	O
sustaining	O
a	O
hip	O
fracture	I:C0019557
during	O
exposure	O
than	O
during	O
nonexposure	O
.	O

In	O
people	O
aged	O
60	O
and	O
older	O
in	O
Norway	O
,	O
those	O
who	O
took	O
an	O
antipsychotic	B:C0040615
drug	I:C0040615
had	O
twice	O
the	O
risk	O
of	O
sustaining	O
a	O
hip	O
fracture	I:C0019557
during	O
exposure	O
than	O
during	O
nonexposure	O
.	O

In	O
people	O
aged	O
60	O
and	O
older	O
in	O
Norway	O
,	O
those	O
who	O
took	O
an	O
antipsychotic	O
drug	I:C0040615
had	O
twice	O
the	O
risk	O
of	O
sustaining	O
a	O
hip	B:C0019557
fracture	I:C0019557
during	O
exposure	O
than	O
during	O
nonexposure	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	B:C0013227
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	O
fracture	I:C0019557
and	O
antipsychotic	O
drug	I:C0040615
use	O
are	O
prevalent	O
in	O
vulnerable	O
older	O
individuals	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	O
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	B:C0019557
fracture	I:C0019557
and	O
antipsychotic	O
drug	I:C0040615
use	O
are	O
prevalent	O
in	O
vulnerable	O
older	O
individuals	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	O
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	O
fracture	I:C0019557
and	O
antipsychotic	B:C0040615
drug	I:C0040615
use	O
are	O
prevalent	O
in	O
vulnerable	O
older	O
individuals	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	O
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	O
fracture	I:C0019557
and	O
antipsychotic	O
drug	I:C0040615
use	B:C0242510
are	O
prevalent	O
in	O
vulnerable	O
older	O
individuals	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	O
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	O
fracture	I:C0019557
and	O
antipsychotic	O
drug	I:C0040615
use	O
are	O
prevalent	O
in	O
vulnerable	O
older	B:C0001792
individuals	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	O
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	O
fracture	I:C0019557
and	O
antipsychotic	O
drug	I:C0040615
use	O
are	O
prevalent	O
in	O
vulnerable	O
older	O
individuals	B:C0027361
.	O

Clinical	B:C0008972
studies	I:C0008972
examining	O
mechanisms	O
or	O
causality	O
of	O
the	O
observed	O
association	O
between	O
antipsychotic	O
drug	I:C0040615
use	O
and	O
excess	O
risk	O
of	O
hip	O
fracture	I:C0019557
are	O
needed	O
.	O

Clinical	O
studies	I:C0008972
examining	O
mechanisms	O
or	O
causality	O
of	O
the	O
observed	O
association	O
between	O
antipsychotic	B:C0040615
drug	I:C0040615
use	O
and	O
excess	O
risk	O
of	O
hip	O
fracture	I:C0019557
are	O
needed	O
.	O

Clinical	O
studies	I:C0008972
examining	O
mechanisms	O
or	O
causality	O
of	O
the	O
observed	O
association	O
between	O
antipsychotic	O
drug	I:C0040615
use	O
and	O
excess	O
risk	O
of	O
hip	B:C0019557
fracture	I:C0019557
are	O
needed	O
.	O

